Document is current
Any future updates will be listed below
-
Authors
,
Seelig, J.
Verheugt, F. W. A.
Hemels, M. E. W.
Illingworth, L.
Lucassen, A.
Adriaansen, H.
Bongaerts, M. C. M.
Pieterse, M.
Herrman, J. P. R.
Hoogslag, P.
Hermans, W.
Groenemeijer, B. E.
Boersma, L. V. A.
Pieper, K.
ten Cate, H.
-
Funding
Funding for this research was provided by:
Bayer HealthCare
- License Information
-
More Information
Article History
Received: 29 November 2019
Accepted: 17 March 2020
First Online: 30 March 2020
Ethics approval and consent to participate
: The study was reviewed and approved by the ethics comittees of each participating centre.
: Not applicable.
: JS is supported by a grant from the Dutch Federation of Anticoagulation clinics (“FNT”). FWAV and MEWH have received honoraria for speaker fees and consultancy honoraria from Bayer Healthcare, Boehringer-Ingelheim, BMS/Pfizer and Daiichi-Sankyo. HTC received compensation for presentations from Boehringer, Bayer, Leo, Daiichi; is advisor for Alveron and receives research support from Bayer and Pfizer. He is an unpaid chairman of the board of the Dutch Federation of Anticoagulation Clinics and National Coordinator for Garfield-AF. HTC is adjunct professor at the Center for Thrombosis and Hemostasis, Gutenberg Medical Center, Mainz, Germany. The other authors declare that they have no competing interests.
